alexa In Vitro And In Vivo Activities Of LCB01-0648 And LCB01-0699 Against Staphylococci
ISSN: 2161-0703

Journal of Medical Microbiology & Diagnosis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

International Conference on Medical and Clinical Microbiology
July 03-04, 2017 Bangkok, Thailand

Jin-Hwan Kwak
Handong Global University, South Korea
ScientificTracks Abstracts: J Med Microb Diagn
DOI: 10.4172/2161-0703-C1-008
Abstract
LCB01-0648 is a new oxazolidinone, which is under preclinical development. In this study, we tested in vitro and in vivo activity of LCB01-0648 against staphylococci. In vitro activity of LCB01-0648 against MSSA, MRSA and LRSA, was evaluated by the agar dilution method as described by the CLSI, and compared with those of linezolid, oxacillin, erythromycin, ciprofloxacin, sparfloxacin, moxifloxacin, gemifloxacin and vancomycin. The MIC90 of LCB01-0648, at which 90% of bacterial strains are inhibited, was 0.5μg/ml against MSSA, MRSA and was below 4μg/ml against LRSA. In vitro activity of CB01-0648 was 4-fold more active than linezolid against MSSA and MRSA. Especially, the antibacterial activity of LCB01-0648 had good antibacterial activities against linezolid-resistant or intermediate S. aureus. LCB01-0648, at the concentration of 8X MIC, showed a bactericidal activity against MSSA and MRSA. In vivo activity of LCB01-0699 which is the active prodrug of LCB01- 0648 was also compared with that of linezolid against systemic infections caused by MSSA, MRSA and LRSA in mice. LCB01- 0699 was more effective than linezolid against systemic infections. In conclusion, LCB01-0648 had potent in vitro and in vivo activity against drug resistant Gram-positive pathogen, including MRSA and LRSA. These results indicate that LCB01-0648 could be a good candidate for further pre-clinical studies.
Biography

Jin-Hwan Kwak has his expertise in evaluation of new antibiotics. He was in charge of developing of new antibiotics including Factive® and Zabifloxacin. He has established various infection model in mice. He is also interested in mode of action of new antibiotics and resistance mechanism in bacteria.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords